- Home
- KRRO vs CATX Comparison
KRRO vs CATX Comparison
Compare KRRO & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- CATX
- Stock Information
- Founded
- KRRO 2014
- CATX 1983
- Country
- KRRO United States
- CATX United States
- Employees
- KRRO N/A
- CATX N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- KRRO Health Care
- CATX Health Care
- Exchange
- KRRO Nasdaq
- CATX Nasdaq
- Market Cap
- KRRO 209.6M
- CATX 182.9M
- IPO Year
- KRRO 2019
- CATX N/A
- Fundamental
- Price
- KRRO $11.42
- CATX $2.57
- Analyst Decision
- KRRO Strong Buy
- CATX Strong Buy
- Analyst Count
- KRRO 7
- CATX 9
- Target Price
- KRRO $85.67
- CATX $12.63
- AVG Volume (30 Days)
- KRRO 89.6K
- CATX 749.8K
- Earning Date
- KRRO 05-07-2025
- CATX 05-12-2025
- Dividend Yield
- KRRO N/A
- CATX N/A
- EPS Growth
- KRRO N/A
- CATX N/A
- EPS
- KRRO N/A
- CATX N/A
- Revenue
- KRRO $4,821,000.00
- CATX $1,471,000.00
- Revenue This Year
- KRRO $20.96
- CATX N/A
- Revenue Next Year
- KRRO N/A
- CATX N/A
- P/E Ratio
- KRRO N/A
- CATX N/A
- Revenue Growth
- KRRO N/A
- CATX N/A
- 52 Week Low
- KRRO $11.00
- CATX $1.60
- 52 Week High
- KRRO $98.00
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- KRRO 34.02
- CATX 53.32
- Support Level
- KRRO $14.54
- CATX $2.34
- Resistance Level
- KRRO $16.68
- CATX $2.94
- Average True Range (ATR)
- KRRO 1.49
- CATX 0.28
- MACD
- KRRO -0.33
- CATX 0.00
- Stochastic Oscillator
- KRRO 6.24
- CATX 55.95
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.